by What is the Non-Hodgkin’s Lymphoma Market Size in 2026?
The global non-Hodgkin’s lymphoma market size was valued at USD 14.10 billion in 2025 and is projected to grow from USD 15.00 billion in 2026 to approximately USD 26.22 billion by 2035, registering a CAGR of 6.40% during the forecast period from 2026 to 2035. The market growth is primarily driven by the rising prevalence of non-Hodgkin’s lymphoma and the increasing demand for targeted and convenient treatment options. In addition, continuous research and development activities focused on innovative CAR-T cell therapies and advanced antibody-based treatments are expected to improve patient survival rates and treatment accessibility, further supporting market expansion.
Get Sample : https://www.precedenceresearch.com/sample/8414
Non-Hodgkin’s Lymphoma Market Key Takeaways
- North America dominated the global non-Hodgkin’s lymphoma market with a share of 40% in 2025.
- Asia-Pacific is expected to grow at the fastest CAGR of 9.1% during the forecast period.
- By treatment type, the chemotherapy segment contributed the highest nmarket share of 30% in 2025.
- By treatment type, the immunotherapy segment is expected to grow at a strong CAGR of 9.3% between 2026 and 2035.
- By drug class, the monoclonal antibodies segment held a major market share of 40% in 2025.
- By drug class, the CAR T-cell therapy segment is expected to expand at the highest CAGR of 10.5% from 2026 to 2035.
- By route of administration, the intravenous (IV) segment captured the highest non-Hodgkin’s lymphoma market share of 50% in 2025.
- By route of administration, the subcutaneous (SC) segment is poised to grow at a healthy CAGR of 8% between 2026 and 2035.
- By end-use industry, the hospitals segment generated the biggest market share of 42% in 2025.
- By end-use industry, the research institutes segment is expanding at the fastest CAGR of 9% between 2026 and 2035.
- By disease subtype, the diffuse large B-cell lymphoma (DLBCL) segment accounted for the largest market share of 40% in 2025.
- By disease subtype, the primary mediastinal B-cell lymphoma (PMBCL) segment is projected to grow at a solid CAGR of 8.5% between 2026 and 2035.
Market Overview
The non-Hodgkin’s lymphoma industry comprises therapies and drugs designed to treat cancers originating in the lymphatic system. The market is being driven by the increasing incidence of lymphoma cases, rapid advancements in immunotherapy, and the growing adoption of targeted therapies that provide more effective and less toxic alternatives to traditional chemotherapy. The industry is witnessing a significant transition toward personalized treatment approaches, particularly with the emergence of CAR T-cell therapies and advanced antibody-based solutions. Leading companies are actively investing in innovative therapies to improve long-term outcomes and offer durable treatment options for patients with aggressive and refractory forms of non-Hodgkin’s lymphoma.
Non-Hodgkin’s Lymphoma Market Trends
- Rapid Adoption of Immunotherapies: CAR-T cell therapies have transformed the treatment of relapsed and refractory NHL, particularly diffuse large B-cell lymphoma and mantle cell lymphoma, offering off-the-shelf efficacy comparable to personalized CAR-T treatments.
- Shift to Earlier Lines of Therapy: Novel targeted agents and immunotherapies are moving from third- or fourth-line to first- or second-line settings, aiming to achieve higher durable responses and potentially curable outcomes earlier in the disease course, thereby transforming the standard of care.
- Expansion of Targeted Therapies and Antibody-Drug Conjugates: The market is seeing strong demand for targeted treatments that minimize systemic toxicity. Key examples include Bruton’s tyrosine kinase inhibitors and antibody-drug conjugates such as Polivy and Zynlonta, which deliver chemotherapy directly to cancer cells.
- Focus on Precision Diagnosis and Personalized Medicine: Advancements in genetic profiling and biomarker testing enable highly customized treatment regimens that prioritize patient quality of life, fueling the market shift toward targeted, less toxic therapies.
Key AI Integration in the Non-Hodgkin’s Lymphoma Market
Artificial intelligence (AI) is transforming the market by improving diagnosis, personalizing treatment, and accelerating drug discovery through analysis of complex imaging and genetic data. AI models analyze histopathological images and PET/CT scans, with studies demonstrating greater accuracy in classifying subtypes. AI aids in predicting patient response to specific treatments and identifying optimal therapeutic pathways by examining tumor heterogeneity, reducing the time and cost associated with drug development.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 14.10 Billion |
| Market Size in 2026 | USD 15.00 Billion |
| Market Size by 2035 | USD 26.22 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 6.40% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
Regional Insights
North America Non-Hodgkin’s Lymphoma Market Size and Growth 2026 to 2035
The North America non-hodgkin’s lymphoma market size was exhibited at USD 5.64 billion in 2025 and is projected to be worth around USD 10.62 billion by 2035, growing at a CAGR of 6.53% from 2026 to 2035.
North America Dominated the Global Non-Hodgkin’s Lymphoma Market in 2025
North America held a major market share of 40% in 2025. This dominance is mainly due to the high incidence of the disease, advanced healthcare infrastructure, and the rapid adoption of high-cost targeted therapies and immunotherapies. The increasing geriatric population, with a high incidence rate of B-cell lymphomas, consistent demand for treatment. Access to advanced oncology centers and specialized diagnostic techniques supports the adoption of premium therapies. Major pharmaceutical companies like Gilead Sciences, Bristol Myers Squibb, and AbbVie lead in CAR-T cell and immunotherapy research.
U.S. Non-Hodgkin’s Lymphoma Market Size and Growth 2026 to 2035
The U.S. non-hodgkin’s lymphoma market size was exhibited at USD 4.23 billion in 2025 and is projected to reach around USD 8.02 billion by 2035, with a CAGR of 6.61% from 2026 to 2035.
U.S. Market Trends
The U.S. plays a crucial role in the market by promoting the rapid adoption of breakthrough CAR-T cell therapies and bispecific antibodies. Supported by significant healthcare investments and advanced clinical infrastructure, the U.S. is aggressively advancing initiatives, including landmark FDA approvals for therapies, solidifying its position as a leader in achieving durable, targeted remissions for non-Hodgkin lymphoma.
Asia-Pacific is Undergoing the Fastest Growth in the Non-Hodgkin’s Lymphoma Market.
Asia-Pacific held 20% of the market share in 2025 and is expected to experience the fastest growth with a CAGR of 9.1% during the predicted timeframe. This growth is driven by an increasing disease burden, rapid improvements in healthcare infrastructure, and the adoption of advanced targeted therapies and immunotherapies. The region is witnessing a surge in NHL cases, particularly influenced by an aging population and changing lifestyle factors, especially in countries like China and India. Increased healthcare spending, improved diagnostic techniques, and better access to advanced treatment options, such as immunotherapy and CAR-T cell therapy, are propelling market growth.
Top Companies in the Non-Hodgkin’s Lymphoma Market
- Roche
- Bristol Myers Squibb
- Novartis
- Gilead Sciences
- Eli Lilly and Co.
- Merck & Co.
- Amgen
- AbbVie
- Pfizer
- Bayer
- AstraZeneca
- Sanofi
- Johnson & Johnson
- Seagen
- Baxter International
Recent Developments
- In February 2026, Lyell Immunopharma initiated dosing for its Phase III PiNACLE – H2H trial, comparing rondecabtagene autoleucel with other CAR-T therapies for relapsed or refractory large B-cell lymphoma. The trial aims to enroll 400 patients and focuses on event-free survival. Earlier studies have shown positive results for ronde-cel in both second- and third-line settings, with high overall response rates. (Source: https://www.clinicaltrialsarena.com)
- In January 2026, Cipla Ltd partnered with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy for blood cancer in South Africa, Algeria, and Morocco, addressing B-cell Non-Hodgkin’s Lymphoma and B-cell Acute Lymphoblastic Leukaemia. The therapy has shown high efficacy in over 500 patients in India. (Source: https://scanx.trade)
- In October 2025, the FDA granted fast-track designation to Enterome’s immunotherapy EO2463 for patients with follicular lymphoma in the “watch-and-wait” setting. Interim results from the phase 2 SIDNEY trial showed a 46% objective response rate, with acceptable tolerability and no severe toxicities for therapy’s development and potential registrational testing. (Source: https://www.onclive.com)
Segments Covered in the Report
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Stem Cell Transplant
By Drug Class
- Monoclonal Antibodies
- Kinase Inhibitors
- Immune Checkpoint Inhibitors
- CAR-T Cell Therapy
- Antineoplastic Agents
By Route of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Oral
By End-Use
- Hospitals
- Oncology Clinics
- Research Institutes
- Homecare
By Disease Subtype
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Check this Report too: Hemophilia Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8414
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
